[Arabinosilcytosine in the treatment of acute leukemia (author's transl)].
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D001927:Brain Diseases / Q000188:drug therapy; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007278:Injections, Spinal; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone
Arabinosil-citosina na terapêutica das leucemias agudas